drugset / Trial / NCT02985021
Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies
Phase 2
Terminated
2 enrolled
Seattle Institute for Biomedical and Clinical Research
Prostate Cancer Foundation · collabVA Puget Sound Health Care System · collab
NaSingle-groupOpen-labelTreatment
Summary
In this study, patients who have metastatic prostate cancer that does not respond to hormone treatment and who have mutations in certain cancer-related genes will be treated with docetaxel and carboplatin chemotherapy.
Timeline
- Start
- 2016-11
- Primary completion
- 2021-04
- Completion
- 2021-04
Outcome
Outcome not reported
Stopped: “Competing studies”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | 5 unknown | — |
| Subject | Docetaxel | Small molecule | 60 mg/m2 | — |